vs
Side-by-side financial comparison of Alphatec Holdings, Inc. (ATEC) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $212.9M, roughly 1.6× Alphatec Holdings, Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs -10.2%, a 23.4% gap on every dollar of revenue. On growth, Alphatec Holdings, Inc. posted the faster year-over-year revenue change (20.4% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $7.7M). Over the past eight quarters, Alphatec Holdings, Inc.'s revenue compounded faster (24.0% CAGR vs 0.4%).
Alphatec Holdings, Inc. is a global medical technology company specializing in spinal surgery solutions. It designs, develops and markets spinal implants, surgical instruments and digital surgery platforms for orthopedic and neurosurgical procedures, serving providers across North America, Europe and core Asia-Pacific markets, addressing degeneration, deformity and trauma spinal pathologies.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ATEC vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $212.9M | $339.0M |
| Net Profit | $-21.7M | $44.7M |
| Gross Margin | 70.2% | 59.7% |
| Operating Margin | -4.1% | 19.9% |
| Net Margin | -10.2% | 13.2% |
| Revenue YoY | 20.4% | -2.7% |
| Net Profit YoY | 34.8% | 19.3% |
| EPS (diluted) | $-0.15 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $212.9M | $339.0M | ||
| Q3 25 | $196.5M | $327.3M | ||
| Q2 25 | $185.5M | $321.4M | ||
| Q1 25 | $169.2M | $330.6M | ||
| Q4 24 | $176.8M | $348.5M | ||
| Q3 24 | $150.7M | $345.5M | ||
| Q2 24 | $145.6M | $336.2M | ||
| Q1 24 | $138.5M | — |
| Q4 25 | $-21.7M | $44.7M | ||
| Q3 25 | $-28.6M | $38.7M | ||
| Q2 25 | $-41.1M | $34.0M | ||
| Q1 25 | $-51.9M | $58.0M | ||
| Q4 24 | $-33.3M | $37.5M | ||
| Q3 24 | $-39.6M | $33.8M | ||
| Q2 24 | $-40.7M | $38.4M | ||
| Q1 24 | $-48.5M | — |
| Q4 25 | 70.2% | 59.7% | ||
| Q3 25 | 69.9% | 59.5% | ||
| Q2 25 | 69.6% | 59.8% | ||
| Q1 25 | 68.6% | 58.4% | ||
| Q4 24 | 68.8% | 55.5% | ||
| Q3 24 | 68.2% | 54.2% | ||
| Q2 24 | 70.5% | 52.0% | ||
| Q1 24 | 70.3% | — |
| Q4 25 | -4.1% | 19.9% | ||
| Q3 25 | -8.1% | 17.9% | ||
| Q2 25 | -7.1% | 16.8% | ||
| Q1 25 | -26.2% | 21.6% | ||
| Q4 24 | -13.5% | 16.9% | ||
| Q3 24 | -22.4% | 15.0% | ||
| Q2 24 | -24.3% | 11.8% | ||
| Q1 24 | -31.3% | — |
| Q4 25 | -10.2% | 13.2% | ||
| Q3 25 | -14.5% | 11.8% | ||
| Q2 25 | -22.2% | 10.6% | ||
| Q1 25 | -30.7% | 17.5% | ||
| Q4 24 | -18.9% | 10.8% | ||
| Q3 24 | -26.3% | 9.8% | ||
| Q2 24 | -27.9% | 11.4% | ||
| Q1 24 | -35.0% | — |
| Q4 25 | $-0.15 | $0.95 | ||
| Q3 25 | $-0.19 | $0.81 | ||
| Q2 25 | $-0.27 | $0.70 | ||
| Q1 25 | $-0.35 | $1.17 | ||
| Q4 24 | $-0.22 | $0.74 | ||
| Q3 24 | $-0.28 | $0.66 | ||
| Q2 24 | $-0.29 | $0.74 | ||
| Q1 24 | $-0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.8M | $363.4M |
| Total DebtLower is stronger | $565.9M | $1.2B |
| Stockholders' EquityBook value | $12.4M | $911.5M |
| Total Assets | $791.2M | $2.5B |
| Debt / EquityLower = less leverage | 45.54× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $160.8M | $363.4M | ||
| Q3 25 | $155.7M | $296.4M | ||
| Q2 25 | $157.1M | $292.9M | ||
| Q1 25 | $153.2M | $306.8M | ||
| Q4 24 | $138.8M | $320.8M | ||
| Q3 24 | $81.0M | $299.3M | ||
| Q2 24 | $99.8M | $344.4M | ||
| Q1 24 | $144.1M | — |
| Q4 25 | $565.9M | $1.2B | ||
| Q3 25 | $559.7M | $1.2B | ||
| Q2 25 | $553.9M | $1.2B | ||
| Q1 25 | $548.4M | $1.2B | ||
| Q4 24 | $576.2M | — | ||
| Q3 24 | $527.7M | — | ||
| Q2 24 | $519.2M | — | ||
| Q1 24 | $514.4M | — |
| Q4 25 | $12.4M | $911.5M | ||
| Q3 25 | $11.5M | $849.2M | ||
| Q2 25 | $23.8M | $882.3M | ||
| Q1 25 | $-85.9M | $820.8M | ||
| Q4 24 | $-14.2M | $906.9M | ||
| Q3 24 | $-1.4M | $878.9M | ||
| Q2 24 | $17.1M | $905.4M | ||
| Q1 24 | $37.6M | — |
| Q4 25 | $791.2M | $2.5B | ||
| Q3 25 | $787.2M | $2.4B | ||
| Q2 25 | $790.3M | $2.5B | ||
| Q1 25 | $785.5M | $2.5B | ||
| Q4 24 | $775.7M | $2.5B | ||
| Q3 24 | $745.9M | $2.5B | ||
| Q2 24 | $768.6M | $2.5B | ||
| Q1 24 | $774.6M | — |
| Q4 25 | 45.54× | 1.34× | ||
| Q3 25 | 48.64× | 1.44× | ||
| Q2 25 | 23.30× | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 30.34× | — | ||
| Q1 24 | 13.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.7M | $93.6M |
| Free Cash FlowOCF − Capex | $7.7M | $87.2M |
| FCF MarginFCF / Revenue | 3.6% | 25.7% |
| Capex IntensityCapex / Revenue | 6.1% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $2.8M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.7M | $93.6M | ||
| Q3 25 | $14.0M | $111.3M | ||
| Q2 25 | $15.5M | $17.4M | ||
| Q1 25 | $-5.0M | $116.6M | ||
| Q4 24 | $10.5M | $43.8M | ||
| Q3 24 | $-5.3M | $48.8M | ||
| Q2 24 | $-11.4M | $-27.4M | ||
| Q1 24 | $-38.4M | — |
| Q4 25 | $7.7M | $87.2M | ||
| Q3 25 | $4.8M | $106.3M | ||
| Q2 25 | $5.2M | $13.6M | ||
| Q1 25 | $-15.0M | $100.9M | ||
| Q4 24 | $8.5M | $35.2M | ||
| Q3 24 | $-21.2M | $39.4M | ||
| Q2 24 | $-45.5M | $-33.1M | ||
| Q1 24 | $-69.8M | — |
| Q4 25 | 3.6% | 25.7% | ||
| Q3 25 | 2.4% | 32.5% | ||
| Q2 25 | 2.8% | 4.2% | ||
| Q1 25 | -8.9% | 30.5% | ||
| Q4 24 | 4.8% | 10.1% | ||
| Q3 24 | -14.1% | 11.4% | ||
| Q2 24 | -31.3% | -9.8% | ||
| Q1 24 | -50.4% | — |
| Q4 25 | 6.1% | 1.9% | ||
| Q3 25 | 4.7% | 1.5% | ||
| Q2 25 | 5.6% | 1.2% | ||
| Q1 25 | 5.9% | 4.7% | ||
| Q4 24 | 1.1% | 2.5% | ||
| Q3 24 | 10.5% | 2.7% | ||
| Q2 24 | 23.4% | 1.7% | ||
| Q1 24 | 22.6% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATEC
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
